iCo is opportunistically looking for available assets that have a previous clinical history. iCo employs various drug delivery technologies, re-doses and/or reformulates existing products in order to enable optimal administration and gain additional intellectual property coverage for the asset. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use or cross pricing issues.
iCo Therapeutics is currently engaged in partnership arrangements with Isis Pharmaceuticals, MedImmune (a division of Astra Zeneca), Immune Pharmaceuticals and the University of British Columbia.
From partner MedImmune, iCo Therapeutics acquired the exclusive, world-wide rights to develop and commercialize iCo-008 for all disease indications. In 2010, iCo granted Immune Pharmaceuticals an option to an exclusive license for the development and commercialization rights to the systemic uses of iCo-008. Immune Pharmaceuticals licensed the systemic rights to iCo-008 in June 2011. iCo retained worldwide exclusive rights to all ocular applications of iCo-008. The partnership with the University of British Columbia resulted in the acquisition of the exclusive, worldwide rights to a novel oral formulation for Amphotericin B to be used for potential systemic fungal and parasitic infections. Phase 1A of the clinical study will advance and is expected to be completed in Q2 2016 and data in Q3 2016.
iCo Therapeutics acquired the exclusive, world-wide rights from partner Isis Pharmaceuticals Inc., to develop and commercialize iCo-007, a second generation antisense inhibitor targeting C-Raf Kinase messenger ribonucleic acid.